Antwerp University Hospital — Sponsor Intelligence | 16 EU Trials

Filter these 16 trials by condition, phase, country and more.

Open in Search →

16 Registered trials

4 Recruiting

11 Completed trials

5 Countries active

40 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase III: 1 Phase II: 9 Phase I/II: 1 Phase III/IV: 1 Phase IV: 3 Phase I (FiH): 1

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

11 of 11 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Pancreatic neuroendocrine tumour 1 Secondary progressive multiple sclerosis 1 Chronic hepatitis B 1 Multiple sclerosis 1 Neuroendocrine tumour 1 Progressive multiple sclerosis 1 Gastroenteropancreatic neuroendocrine tumour disease 1 Primary progressive multiple sclerosis 1 Colon cancer stage III 1 Myocarditis post infection 1 Pleural mesothelioma malignant 1 Colon cancer stage II 1

Top IMPs

WT1 LAMP MRNA DC 4 ATEZOLIZUMAB 1 CARBOPLATIN 1 CISPLATIN 1 DIMETHYL FUMARATE 1 ENTECAVIR 1 ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL 1 FINGOLIMOD 1 GLATIRAMER ACETATE 1 INTERFERON BETA-1A 1 IPILIMUMAB 1 METFORMIN HYDROCHLORIDE 1

All trials

16 total

ABT-199 (Venetoclax) and Purine analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia (ApoAML… Pending

2024-510717-15-00 Phase I/II 1 country
NEoadjuvant Chemotherapy and Immunotherapy for a selected group of inoperable pleural Mesothelioma patients (NECIM): a feasibility study Recruiting

2023-504302-11-02 Phase II 1 country CARBOPLATIN; CISPLATIN; IPILIMUMAB; NIVOLUMAB; PEMETREXED
Myocarditis Therapy with Steroids in patients with a Mildly Reduced ejection fraction (MYTHS-MR) Recruiting

2022-501547-33-01 Phase III/IV 4 countries METHYLPREDNISOLONE SODIUM SUCCINATE
Continuing Somatostatin Analogues Upon progression in Neuroendocrine tumour pAtients (SAUNA trial) Recruiting

2022-502703-30-00 Phase IV 2 countries
Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid m… Recruiting

2024-515293-27-00 Phase II 1 country ATEZOLIZUMAB; WT1 LAMP MRNA DC
Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination to prevent relapse in adult patients with acute myeloid leukemia: a multicent… Ended

2024-515292-35-00 Phase II 1 country WT1 MRNA DC
Controlled Interruption of Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Infections Ended

2024-511016-25-00 Phase II 1 country ENTECAVIR; TENOFOVIR ALAFENAMIDE; TENOFOVIR DISOPROXIL
A study concerning the influence of tubal flushing with oil on pregnancy and live birth in women with fertility problems Ended

2023-508896-35-00 Phase IV 1 country ETHYL ESTERS OF IODISED FATTY ACIDS FROM POPPYSEED OIL
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country DIMETHYL FUMARATE; FINGOLIMOD; GLATIRAMER ACETATE; INTERFERON BETA-1A; METFORMIN…
A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients Ended

2022-502798-40-00 Phase III 1 country
Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma Ended

2024-515291-13-00 Phase II 1 country WT1 LAMP MRNA DC
First-in-human interleukin-15-transpresenting Wilms’ tumor protein 1-targeting autologous dendritic cell vaccination in cancer patients Ended

2024-515296-35-00 Phase I (FiH) 1 country WT1/IL15/IL15RA MRNA DC
MyKid-study: a study to examine the effect and safety of an injection of Mydrane® into the eye of children who will undergo cataract surgery Ended

2023-504173-21-00 Phase IV 1 country PHENYLEPHRINE HYDROCHLORIDE, TROPICAMIDE, LIDOCAINE HYDROCHLORIDE
Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic… Ended

2024-515295-12-00 Phase II 1 country WT1 LAMP MRNA DC
First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma Ended

2024-517970-35-00 Phase II 1 country WT1 LAMP MRNA DC
A controlled phase II clinical trial evaluating the safety and efficacy of myelin peptide-loaded tolDC as treatment for Multiple Sclerosis Ended

2024-512891-37-00 Phase II 2 countries TOLDC

Showing 1–16 of 16 trials

← All sponsors A–Z